Aligos Therapeutics (ALGS) Operating Margin (2021 - 2026)

Aligos Therapeutics (ALGS) has reported Operating Margin for 6 consecutive years, with 951.55% the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin rose 523591.0% year-over-year to 951.55%; the trailing twelve-month figure through Jun 2026 stood at 2112.14% (up 39437.0% YoY), and the FY2025 full-year result was 4024.93%, down 155598.0% from the prior year.
• Operating Margin climbed to 951.55% in Q1 2026 per ALGS's latest filing, from 12907.69% in the prior quarter.
• Across five years, Operating Margin topped out at 445.76% in Q2 2023 and bottomed at 12907.69% in Q4 2025.
• Historically, Operating Margin has averaged 2532.77% across 5 years, with a median of 1383.0% in 2022.
• The sharpest annual moves came in 2022 and 2025: Operating Margin soared 969878 bps in 2022, then sank 951446 bps in 2025.
• Over 5 years, Operating Margin stood at 641.28% in 2022, then plunged by 102 bps to 1294.03% in 2023, then tumbled by 162 bps to 3393.23% in 2024, then plunged by 280 bps to 12907.69% in 2025, then surged by 93 bps to 951.55% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 951.55%, 12907.69%, and 3827.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.